Cargando…

Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma

A 51-year-old male patient had four times of massive hematochezia episode three days before arrival. Carbohydrate antigen (CA) 19-9 level was extremely elevated. Computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography identified 5.7 cm sized periampullar...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Dongjin, Park, Bo Gyeom, Jung, Dawn, Hwang, Ho Kyoung, Kim, Sung Hyun, Hong, Seung Soo, Kang, Chang Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Hepato-Biliary-Pancreatic Surgery 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947377/
https://www.ncbi.nlm.nih.gov/pubmed/36536505
http://dx.doi.org/10.14701/ahbps.22-069
_version_ 1784892539388559360
author Seo, Dongjin
Park, Bo Gyeom
Jung, Dawn
Hwang, Ho Kyoung
Kim, Sung Hyun
Hong, Seung Soo
Kang, Chang Moo
author_facet Seo, Dongjin
Park, Bo Gyeom
Jung, Dawn
Hwang, Ho Kyoung
Kim, Sung Hyun
Hong, Seung Soo
Kang, Chang Moo
author_sort Seo, Dongjin
collection PubMed
description A 51-year-old male patient had four times of massive hematochezia episode three days before arrival. Carbohydrate antigen (CA) 19-9 level was extremely elevated. Computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography identified 5.7 cm sized periampullary duodenal cancer with regional metastatic lymph nodes and vascular invasion to aberrant right hepatic artery, main portal vein, and superior mesenteric vein. Diagnosed as duodenal adenocarcinoma through endoscopic biopsy, 16 times of FOLFIRI (5-fluorouracil, leucovorin, irinotecan) was conducted. The regimen changed to XELOX (capecitabine, oxaliplatine), four times of administration was done, and the CA19-9 level dramatically decreased. The tumor decreased to 2.1 cm. After R0 laparoscopic pylorus preserving pancreatoduodenectomy, no adjuvant therapy was given. No sign of recurrence or metastasis was reported, and the patient reached complete remission after five years. We reported a case where neoadjuvant chemotherapy for locally advanced duodenal adenocarcinoma was shown to be effective.
format Online
Article
Text
id pubmed-9947377
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Korean Association of Hepato-Biliary-Pancreatic Surgery
record_format MEDLINE/PubMed
spelling pubmed-99473772023-02-24 Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma Seo, Dongjin Park, Bo Gyeom Jung, Dawn Hwang, Ho Kyoung Kim, Sung Hyun Hong, Seung Soo Kang, Chang Moo Ann Hepatobiliary Pancreat Surg Case Report A 51-year-old male patient had four times of massive hematochezia episode three days before arrival. Carbohydrate antigen (CA) 19-9 level was extremely elevated. Computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography identified 5.7 cm sized periampullary duodenal cancer with regional metastatic lymph nodes and vascular invasion to aberrant right hepatic artery, main portal vein, and superior mesenteric vein. Diagnosed as duodenal adenocarcinoma through endoscopic biopsy, 16 times of FOLFIRI (5-fluorouracil, leucovorin, irinotecan) was conducted. The regimen changed to XELOX (capecitabine, oxaliplatine), four times of administration was done, and the CA19-9 level dramatically decreased. The tumor decreased to 2.1 cm. After R0 laparoscopic pylorus preserving pancreatoduodenectomy, no adjuvant therapy was given. No sign of recurrence or metastasis was reported, and the patient reached complete remission after five years. We reported a case where neoadjuvant chemotherapy for locally advanced duodenal adenocarcinoma was shown to be effective. The Korean Association of Hepato-Biliary-Pancreatic Surgery 2023-02-28 2022-12-20 /pmc/articles/PMC9947377/ /pubmed/36536505 http://dx.doi.org/10.14701/ahbps.22-069 Text en Copyright © 2023 by The Korean Association of Hepato-Biliary-Pancreatic Surgery https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Seo, Dongjin
Park, Bo Gyeom
Jung, Dawn
Hwang, Ho Kyoung
Kim, Sung Hyun
Hong, Seung Soo
Kang, Chang Moo
Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
title Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
title_full Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
title_fullStr Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
title_full_unstemmed Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
title_short Pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
title_sort pancreatoduodenectomy following neoadjuvant chemotherapy in duodenal adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947377/
https://www.ncbi.nlm.nih.gov/pubmed/36536505
http://dx.doi.org/10.14701/ahbps.22-069
work_keys_str_mv AT seodongjin pancreatoduodenectomyfollowingneoadjuvantchemotherapyinduodenaladenocarcinoma
AT parkbogyeom pancreatoduodenectomyfollowingneoadjuvantchemotherapyinduodenaladenocarcinoma
AT jungdawn pancreatoduodenectomyfollowingneoadjuvantchemotherapyinduodenaladenocarcinoma
AT hwanghokyoung pancreatoduodenectomyfollowingneoadjuvantchemotherapyinduodenaladenocarcinoma
AT kimsunghyun pancreatoduodenectomyfollowingneoadjuvantchemotherapyinduodenaladenocarcinoma
AT hongseungsoo pancreatoduodenectomyfollowingneoadjuvantchemotherapyinduodenaladenocarcinoma
AT kangchangmoo pancreatoduodenectomyfollowingneoadjuvantchemotherapyinduodenaladenocarcinoma